#1 Clinical Trials Search in Europe

Clemastine Fumarate

Clemastine fumarate, traditionally used as an antihistamine, is being investigated in several clinical trials for its potential as a remyelinating agent. These studies aim to evaluate its efficacy in treating conditions like multiple sclerosis, optic neuritis, and other demyelinating diseases. The trials are exploring how clemastine fumarate might help repair damaged myelin in the central nervous system, potentially improving neurological function and slowing disease progression.

Table of Contents

What is Clemastine Fumarate?

Clemastine Fumarate is a medication that has been used for many years as an antihistamine to treat allergies. It’s known by several brand names, including Tavist, Dayhist, and Dayhist Allergy[1]. Originally approved by the Food and Drug Administration (FDA) in 1977 for treating allergic rhinitis (seasonal allergies), it became available over-the-counter in 1992[2].

However, recent research has shown that Clemastine Fumarate may have potential benefits beyond treating allergies. Scientists are now exploring its use in treating various neurological conditions, particularly those involving damage to the protective coating around nerve fibers in the brain and spinal cord, called myelin[3].

Conditions Treated with Clemastine Fumarate

While Clemastine Fumarate is primarily known for treating allergies, ongoing research is investigating its potential in treating several other conditions:

  • Multiple Sclerosis (MS): This is a condition where the immune system mistakenly attacks the myelin in the central nervous system. Researchers are studying whether Clemastine Fumarate can help repair this damage[3][1].
  • Optic Neuritis: This is inflammation of the optic nerve, which can cause vision problems. Studies are looking at whether Clemastine Fumarate can help repair the damage and improve vision[4].
  • Late-life Depression: Some research is exploring whether Clemastine Fumarate can improve brain function in older adults with depression[5].
  • Williams Syndrome: This is a rare genetic disorder that affects various parts of the body. A study is looking at whether Clemastine Fumarate can help with neurodevelopmental delays associated with this condition[6].

How Clemastine Fumarate Works

Clemastine Fumarate works in two main ways:

  1. As an antihistamine: It blocks the effects of histamine, a substance your body produces during an allergic reaction. This helps reduce allergy symptoms like sneezing, itching, and runny nose[7].
  2. As a potential remyelinating agent: Recent research suggests that Clemastine Fumarate might help promote the repair of damaged myelin in the nervous system. Myelin is the protective coating around nerve fibers that helps them transmit signals efficiently. In conditions like multiple sclerosis, this coating is damaged. Scientists believe Clemastine Fumarate might encourage the body to produce new myelin, potentially improving nerve function[3][1].

Ongoing Research and Potential New Uses

Several clinical trials are currently underway to explore new potential uses for Clemastine Fumarate:

  • Multiple Sclerosis: Researchers are studying whether Clemastine Fumarate can help repair myelin damage in people with MS. They’re using advanced brain imaging techniques to measure changes in the brain’s white matter (which contains myelinated nerve fibers)[1][2].
  • Optic Neuritis: A study is looking at whether Clemastine Fumarate can help improve vision in people who have experienced optic neuritis, which is often associated with MS[4].
  • Late-life Depression: Researchers are investigating if Clemastine Fumarate can improve brain function and boost the effectiveness of antidepressants in older adults with depression[5].
  • Williams Syndrome: A study is exploring whether Clemastine Fumarate can help improve cognitive, motor, and social skills in children with Williams Syndrome[6].
  • Cardiovascular Surgery: One study is looking at whether Clemastine Fumarate can help reduce allergic reactions during heart surgery[8].

How Clemastine Fumarate is Administered

The way Clemastine Fumarate is given can vary depending on what it’s being used for:

  • For allergies, it’s typically taken orally as a tablet or syrup.
  • In research studies for MS and other conditions, it’s often given as tablets, with doses ranging from 4 mg to 12 mg per day[3][1].
  • In some studies, it’s given in combination with other medications[9].
  • The duration of treatment can vary from a few weeks to several months, depending on the condition being treated and the specific research protocol.

Potential Side Effects

Like all medications, Clemastine Fumarate can cause side effects. Common side effects may include:

  • Drowsiness or sleepiness
  • Dizziness
  • Headache
  • Dry mouth
  • Fatigue
  • Stomach discomfort
  • Constipation
  • Nausea[2]

In some studies, researchers are paying special attention to how Clemastine Fumarate affects fatigue levels, as fatigue is a common symptom in conditions like multiple sclerosis[1].

Precautions and Considerations

While Clemastine Fumarate is generally considered safe, there are some important things to keep in mind:

  • It may cause drowsiness, so you should be careful when driving or operating machinery.
  • It’s not currently approved for treating conditions other than allergies. Its use for other conditions is still being researched.
  • If you’re participating in a clinical trial, you may need to stay on your regular medications and avoid other experimental treatments[10].
  • Always inform your healthcare provider about all medications you’re taking, including over-the-counter drugs and supplements.
  • If you’re pregnant or breastfeeding, discuss the risks and benefits with your doctor before taking Clemastine Fumarate.

Remember, while the potential new uses of Clemastine Fumarate are exciting, more research is needed to fully understand its effects and safety for conditions other than allergies. Always consult with a healthcare professional before starting or changing any medication regimen.

Aspect Details
Main Purpose To assess clemastine fumarate as a potential remyelinating agent in demyelinating diseases
Conditions Studied Multiple sclerosis, optic neuritis, other demyelinating diseases
Primary Outcomes Changes in visual evoked potentials, MRI measures (MWF, MTR), visual acuity
Secondary Outcomes Changes in retinal nerve fiber layer thickness, disability scores, fatigue levels
Dosage Varies by study, typically 4-12 mg daily
Duration 3-9 months, with some studies including longer follow-up periods
Safety Monitoring Side effects, particularly fatigue, drowsiness, and other known antihistamine effects
Innovative Aspects Use of advanced MRI techniques, including ultrashort echo time (UTE) MRI

FAQ

  • What is clemastine fumarate being studied for in these clinical trials? Clemastine fumarate is being studied primarily for its potential as a remyelinating agent in conditions like multiple sclerosis, optic neuritis, and other demyelinating diseases. It's being investigated for its ability to repair damaged myelin in the central nervous system.
  • How is the effectiveness of clemastine fumarate being measured in these trials? The effectiveness is being measured through various methods, including visual evoked potentials (VEP), magnetic resonance imaging (MRI) techniques like myelin water fraction (MWF) and magnetization transfer ratios (MTR), optical coherence tomography (OCT), and clinical assessments of vision and neurological function.
  • What are some of the potential benefits being investigated? Potential benefits being investigated include improved visual function, reduced disability progression, enhanced myelin repair, and overall improvement in neurological symptoms associated with demyelinating diseases.
  • Are there any side effects or safety concerns being monitored? Yes, the trials are monitoring for side effects, with a particular focus on fatigue, which is a common symptom in multiple sclerosis. Other potential side effects being watched include drowsiness, dizziness, and dry mouth, which are known side effects of clemastine fumarate when used as an antihistamine.
  • How long do these clinical trials typically last? The duration of these trials varies, but many last between 3 to 9 months, with some including longer follow-up periods of up to 36 months to assess long-term effects and safety.

Ongoing Clinical Trials on Clemastine Fumarate

  • Study on the Safety and Effectiveness of Tregs and Rituximab for Children with Early Stage Type 1 Diabetes

    Recruiting

    1 1
    Investigated drugs:
    Poland

  • Study on the Safety and Dosage of GD2IL18CART for Patients with Relapsed or Refractory GD2 Positive Solid Cancers

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany

  • Efficacy and Safety of Clemastine Fumarate in Children and Adults with Pitt‑Hopkins Syndrome: A Randomized Placebo‑Controlled Trial

    Not yet recruiting

    1 1
    Investigated drugs:
    The Netherlands

  • Study on ABCB5+ MSCs for Recessive Dystrophic and Junctional Epidermolysis Bullosa Patients

    Not yet recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Croatia Denmark France Germany Greece +6

Glossary

  • Remyelination: The process of repairing and rebuilding the myelin sheath around nerve fibers that has been damaged in demyelinating diseases.
  • Multiple Sclerosis (MS): A chronic disease affecting the central nervous system, where the immune system attacks the protective covering of nerve fibers, causing communication problems between the brain and the rest of the body.
  • Optic Neuritis: Inflammation of the optic nerve that can cause sudden, reduced vision in the affected eye.
  • Myelin: A fatty substance that surrounds nerve fibers, helping them transmit electrical signals quickly and efficiently.
  • Visual Evoked Potential (VEP): A test that measures the electrical activity in the brain in response to visual stimuli, used to assess the function of the visual pathway.
  • Magnetic Resonance Imaging (MRI): A medical imaging technique that uses strong magnetic fields and radio waves to produce detailed images of the inside of the body.
  • Myelin Water Fraction (MWF): A measure derived from MRI that estimates the amount of myelin in brain tissue.
  • Magnetization Transfer Ratio (MTR): An MRI technique used to indirectly measure the amount of myelin in brain tissue.
  • Optical Coherence Tomography (OCT): A non-invasive imaging test that uses light waves to take cross-section pictures of the retina.
  • Expanded Disability Status Scale (EDSS): A method of quantifying disability in multiple sclerosis and monitoring changes in the level of disability over time.

References

  1. https://clinicaltrials.gov/study/NCT05359653
  2. https://clinicaltrials.gov/study/NCT06065670
  3. https://clinicaltrials.eu/trial/study-on-clemastine-and-fampridine-for-patients-with-multiple-sclerosis-and-internuclear-ophthalmoparesis/
  4. https://clinicaltrials.gov/study/NCT02521311
  5. https://clinicaltrials.gov/study/NCT06591091
  6. https://clinicaltrials.gov/study/NCT06315699
  7. https://clinicaltrials.gov/study/NCT02613091
  8. https://clinicaltrials.gov/study/NCT03826004
  9. https://clinicaltrials.gov/study/NCT01239719
  10. https://clinicaltrials.gov/study/NCT02040298